CA Patent

CA3156009A1 — Combination therapy with cgrp antagonists

Assigned to Allergan Pharmaceuticals International Ltd · Expires 2021-04-01 · 5y expired

What this patent protects

The invention relates to methods of treating headache, migraine and related symptoms by administering a calcitonin gene-related peptide (CGRP) antagonist and a short-acting CGRP antagonist. Specifically, the invention relates to a method of treating, preventing, alleviating, or r…

USPTO Abstract

The invention relates to methods of treating headache, migraine and related symptoms by administering a calcitonin gene-related peptide (CGRP) antagonist and a short-acting CGRP antagonist. Specifically, the invention relates to a method of treating, preventing, alleviating, or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient: (a) a first peptide antagonist associated to the calcitonin gene (CGRP agonist) and (b) a second CGRP antagonist, the first CGRP antagonist being an antibody and the second CGRP antagonist exhibiting a plasma half-life in humans of at most about 60 hours.

Drugs covered by this patent

Patent Metadata

Patent number
CA3156009A1
Jurisdiction
CA
Classification
—
Expires
2021-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Pharmaceuticals International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.